Publications
Publications - Katherine Lee
1. Lovering,
F*.; Morgan, P.; Allais, C.; Aulabaugh, A;
Brodfuehrer, J.; Chang, J; Coe, J.; Ding, W.; Dowty, H.; Fleming, M.;
Frisbie, R.; Guzova, J.; Hepworth, D.; Jasti, J.; Kortum, S.; Kurumbail, R.;
Mohan, S.; Papaioannou, N.; Strohbach, J. W.; Vincent, F.; Lee, K.; Zapf, C. W.; Rational Approach to Highly Potent and
Selective Apoptosis Signal-Regulating Kinase 1 (ASK1) inhibitors. Eur. J. Med. Chem. 2018, 145, 606-621. doi: 10.1016/j.ejmech.2017.12.041
2.
K.L. Lee*, C.M. Ambler, D.R.
Anderson, B.P. Boscoe, A.G. Bree, J.I. Brodfuehrer, J.S. Chang, C.
Choi, S. Chung, K.J. Curran, J.E. Day, C.M. Dehnhardt, K.
Dower, S.E. Drozda, R.K. Frisbie, L.K. Gavrin, J.A. Goldberg, S. Han, M. Hegen,
D.Hepworth, H.R. Hope, S. Kamtekar, I.C. Kilty, A. Lee, L.-L. Lin, F.E.
Lovering, M.D. Lowe, J.P. Mathias, H.M. Morgan, E.A. Murphy, N. Papaioannou, A.
Patny, B.S. Pierce, V.R. Rao, E. Saiah, I.J. Samardjiev, B.M. Samas, M.W.H.
Shen, J.H. Shin, H.H. Soutter, J.W. Strohbach, P.T. Symanowicz, J.R. Thomason,
J.D. Trzupek, R. Vargas, F. Vincent, J. Yan, C.W. Zapf, and S.W. Wright*,
“Discovery of clinical candidate
1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide
(PF-06650833), a potent, selective inhibitor of interleukin-1 receptor
associated kinase 4 (IRAK4), by fragment-based drug design.” J. Med. Chem. 2017, 60, 5521-5542.
3.
S.
Vollmer, T. Zhang, N. Gray, K. Lee,
V. Rao, and P. Cohen, "The
mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-Like
receptor agonists." Biochemical
Journal, 2017, 474, 2027-2038.
4.
L.
Cushing, A. Winkler, S. Jelinsky, K. Lee,
W. Krouver, R. Hatwin, V.R. Rao, M. Fleming, L.-L. Lin, “IRAK4 kinase activity
mediates IRF5 activation via IKKb and TAK1.” J. Biol. Chem. 2017, 292, 18689-18692. doi:
10.1074/jbc.M117.796912.
5. P.
Thakker, S. Marusic, N.L. Stedman, K.L.
Lee, J.C. McKew, A. Wood, S.J. Goldman, M.W. Leach, M. Collins, V.K.
Kuchroo, S.F. Wolf, J.D. Clark, M. Hassan-Zahraee, “Cytosolic phospholipase A2a blockade abrogates disease
during the tissue-damage effector phase of experimental autoimmune encephalomyelitis
by its action on APCs.” J. Immunol., 2011, 187(4), 1986-1997.
6.
C.L.
Nickerson-Nutter, D. Goodwin, M.W.H. Shen, C. Damphousse, W. Duan, T.A. Samad,
J.C. McKew, K.L. Lee, M.M. Zaleska,
N. Mollova, J.D. Clark, “The cPLA2a inhibitor Efipladib decreases nociceptive
responses without affecting PGE2 levels in the cerebral spinal fluid.” Neuropharmacology, 2011, 60, 633-641.
7. L.
Chen*, W. Wang, K.L. Lee, M.W.H. Shen, J.L. Wu, E.A. Murphy,
W. Zhang, X. Xu, S. Tam, C. Nickerson-Nutter, D.G.
Goodwin, J.D. Clark, and J.C. McKew, “Reactions of functionalized sulfonamides:
Application to lowering the lipophilicity of cPLA2a inhibitors.” J.
Med. Chem., 2009, 52, 1156-1171.
8.
S. Marusic*, P. Thakker*, J. W.; Pelker, N. Stedman, K.L. Lee,
J.C. McKew, L. Han, X. Xu, S.F. Wolf, A.J. Borey, J. Cui, M. W. Shen, F.
Donahue, M. Hassan-Zahree, M.W. Leach, T. Shimizu, J.D. Clark, “Selective blockade of
cytosolic phospholipase A2a prevents experimental autoimmune encephalomyelitis
and diminishes development of Th1 and Th17 responses in mice.” Journal of
Neuroimmunology, 2008, 204, 29-37.
9. M.K.
Ramarao*, M. Shen, E. Murphy, W. Duan, Y.
Zhao, J. McKew, K.L. Lee, P. Thakker, M.L. Behnke, and J.D. Clark*,
“Thermodynamic characterization of cPLA2a inhibitors.” Analytical
Biochemistry, 2008, 383, 217-225.
10.
J.C.
McKew*, K.L. Lee, M.W.H. Shen, P. Thakker, M.A. Foley, M.L. Behnke, B.
Hu, F.-W. Sum, S. Tam, Y. Hu, L. Chen, S.J. Kirincich, R. Michalak, J. T.on, M.
Ipek, K. Wu, L. Wooder, M.K. Ramarao, E.A. Murphy, D.G. Goodwin, L.
Albert, X. Xu, F. Donahue, M.S. Ku, J. Keith, C.L. Nickerson-Nutter,
W. M. Abraham, C. Williams, M. Hegen, and J.D. Clark, “Indole
cPLA2a inhibitors: Discovery and in vitro and in vivo characterization
of Efipladib and WAY-196025.” J. Med. Chem., 2008, 51,
3388-3413.
11. K.L. Lee*, M.L. Behnke, M.A. Foley, L. Chen, W. Wang,
R. Vargas, J. Nunez, S. Tam, N. Mollova, X. Xu, M.W.H. Shen, M. K. Ramarao,
D.G. Goodwin, C.L. Nickerson-Nutter, C. Williams, W.M. Abraham, J.D.
Clark, and J.C. McKew, “Benzenesulfonamide indole inhibitors of cytosolic phospholipase
A2a: Optimization of in vitro potency and rat pharmacokinetics
for oral efficacy.” Bioorg. Med. Chem., 2008, 16,
1345-1358.
12. K.L.
Lee*; M.A. Foley, L. Chen, M.L. Behnke, F.E. Lovering, S.J.
Kirincich, J. Shim, S.Tam, M.W.H. Shen, S. Khor, X. Xu, D.G. Goodwin, M.K.
Ramarao, C. Nickerson-Nutter, F. Donahue, M.S. Ku, J.D. Clark, and J.C. McKew,
“Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2a.”
J. Med. Chem. 2007, 50, 1380-1400.
13. K.L.
Lee, J.B. Goh, S.F. Martin, “Novel entry to the Ergot alkaloids
via ring closing metathesis.” Tetrahedron
Letters 2001, 42(9), 1635-1638.
14. K.M. Shea, K.L. Lee,
R.L. Danheiser, “Synthesis
and properties of 9-alkyl- and 9-arylcyclopenta[a]phenalenes.” Organic
Letters 2000, 2(15), 2353-2356.
15. K.L. Lee
and R.L. Danheiser, “(Trimethylsilyl)allene.” Encyclopedia of Reagents for Organic Synthesis, 2001.
16. K.L. Lee
and R.L. Danheiser, “1-Methyl-1-(trimethylsilyl)allene.” Encyclopedia of Reagents for Organic Synthesis, 2001.
